Oregon Health & Science University researchers published findings in JAMA Network Open regarding the state’s regulated psilocybin program. The study represents the first multisite evaluation of Oregon’s legalized psilocybin market.
The research team monitored 346 individuals who participated in single sessions at 24 licensed service centers. Participants accessed these services between November 2024 and June 2026. They reported their mental state through a web-based portal at baseline and at one week, one month, and three months post-session.
Ninety percent of the enrolled participants continued reporting data through the full three-month period. Lead author Todd Korthuis, M.D., M.P.H., noted that safety profiles matched those seen in clinical settings. He stated, “Safety was very similar to what we’ve seen with psychedelics in clinical settings,” in a statement reported by OHSU News.
Most participants reported relief from symptoms of anxiety, depression, and post-traumatic stress disorder after three months. Nearly two-thirds of the group declared the experience to be among the most meaningful of their lives. Specifically, about 65 percent cited it as one of the top 10 most meaningful experiences of their lives.
Ninety-one and a half percent of respondents described their experience as positive after one month. Only seven participants reported the experience as harmful three months after their use of psilocybin. Korthuis observed that this low incidence of adverse events may reflect clients who were healthier overall than typical clinical trial participants.
Senior co-author Adrianne R. Wilson-Poe, Ph.D., emphasized the scale of the data collection. She said, “This is the first large-scale study to monitor the safety and mental health symptoms of real people in the real world,” according to the report.
OHSU President Shereef Elnahal, M.D., highlighted the relevance of these results for public health policy. He noted the study provides important insight for policymakers considering programs for mental health conditions. These conditions include PTSD and substance use disorders affecting America’s military veterans.
More than 20,000 people have accessed Oregon licensed psilocybin services to date according to data tracked by the Oregon Health Authority. The study findings will be presented at the Psychedelic Innovation Summit in Portland. This event is co-hosted by OHSU and the Healing Advocacy Fund.
Korthuis cautioned that psilocybin is not appropriate for people with psychosis, bipolar disorder, or those who are pregnant. He advised that people with serious mental health or medical conditions should talk with their health care providers before seeking services.
Lawsuit Filed Over Facility Odor Residents of Rock Hill are suing Proper Brands, arguing that a "skunky" smell from the…
Expert Warning On Outdated Testing Dr Georges Petitjean has warned that workplace drug testing has failed to keep pace with…
Event Details Shore House Canna, an adult-use dispensary in West Cape May, New Jersey, will host its 3rd Annual Fall…
Sabalenka Stops Play Over Cannabis Smell Top seed Aryna Sabalenka briefly halted her US Open third-round match against Kamilla Rakhimova…
CBDD Signs Definitive Agreement to Acquire BioCannabis CBD of Denver, Inc. (OTCID: CBDD) announced on September 15, 2026 that it…
Seventh Annual New Jersey Cannabis Convention Set NECANN brings the New Jersey Cannabis Convention back to the Atlantic City Convention…
